Drug Profile
Canerpaturev - Takara Bio
Alternative Names: C-REV; HF-10; Msc-2; TBI-1401Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Ms Science; Nagoya University
- Developer Takara Bio; University of Utah
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Malignant melanoma
- No development reported Head and neck cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (Intratumoural, Injection)
- 09 Nov 2021 Otsuka Pharmaceutical terminates licensing agreement with Takara Bio for Canerpaturev in Japan
- 20 Jan 2021 Canerpaturev is still in phase I trial for Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (Otsuka Pharmaceuticals pipeline, January 2021) (NCT03252808)